REFERENCES

REFERENCES

Abe S, Arima S, and Yamashita T (1994):
Early assessment of reperfusion therapy using cardiac troponin
J Am Coll Cardiol, 23: 1382.

Adams JIII, Abendschein B and Jaffe A (1993):
Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s.
Circulation, 88: 750.

Adams JE, Bodor GS and Davila-Roman VG (1993):
Cardiac troponin 1: A marker with high specificity for cardiac injury.
Circulation, 88: 101.

Adams JE, Schechtman KB and Landt Y (1994a):
Comperable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponine I.
Clin Chem, 40: 1291.

Adams JE, Sicard GA and Allan BT (1994b):
Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I.
N Engl J Med, 330: 670.

Alfthan G, Pekkanen JK and Jauhiainen M (1994):
Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective finnish population based study.
Atherosclerosis, 106: 9.

Andersson A, Brattstrom LE, Huftberg B and Isaksson A (1993):
Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolum derivatization.
Clin Chem, 39: 1590.

Andersson A, Brattstrom LE, Isaksson A, Israelsson B and Hultberg B (1989):
Determination of homocysteine in plasma by ion exchange chromatography.
Scond J Clin Lab Invest, 49: 445.

Antman EM, Grudzien C and Sacks D (1995a):
Evaluation of a new bedside assay for detection of serum cardiac troponin T.
J Am, 273: 279.

Antman EM, Tanasijevic MJ and Cannon CP (1995b):
Cardiac troponin I on admission predicts death by 42 days in unstable angina and improved survival with an early invasive strategy: Results from TIMI IIIB.
Circulation, 92: 1-663.

Apple F (1992):
Creatine kinase MB.
Lab Med, 23: 298.

Araki A and Sako Y (1987):
Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with flourescence detection.
J Chromatogr, 422: 43.

Austin MA, Breslow JL and Hennekens CH (1988):
Low density lipoprotein subclass patterns and risk of myocardial infarction.
JAMA, 260: 1917.

Austin MA, King MC, Vranizan KM and Krauss RM (1990):
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
Circulation, 82: 195.

Baeyens W, Van Der Weken G and De Moerlosse P (1987):
Effects of reducing agents on the determination of thiolic compounds in the presence of their disulfides using bimane procolumn derivatization.
Gromatographia, 23: 717.

Bakker AJ, Gorgles JPMC and Van Vlies B (1994):
Contribution of creatinine kinase MB activity in serum after extraction with a monoclonal antibody specific to the MB isoenzyme.
Clin Chem, 32: 657.

Bellamy MF, Ramsey MW, Good Fellow J and Brownlee M (1996):
Hyperhomocysteinemia and endothelial dysfunction with low vitamin B12/folate status.
Circulation, 94 (Suppl.): I-462.

Bergmark C, Manssor MA, Swedenborg J and deFaire U (1993):
Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50: effect of smoking and extent of disease.
Eur Vasc Surg, 7: 391.

Blair SN, Kohl HW and Paffenberger RS (1989):
Physical fitness and all-cause mortality. A prospective study of healthy men and women.
JAMA, 262: 2395.

Blankenhorn DH, Malinow R and Mack WJ (1991):
Colestipol plus niacin therapy elevates plasma homocysteine levels.
Coron Art Dis, 2: 357.

Boers GHJ, Smals AGH and Trijbles FJM (1985):
Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.
N Engl J Med, 313: 709.

Bostom AG, Brosnan JT, Hall B, Nadeau MR and Selhub J (1995):
Net uptake of plasma homocysteine by the rat kidney in vivo.
Atherosclerosis, 116: 59.

Bostom AG, Shemin D and Lapans KL (1996):
High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients.
Kidney Int, 49: 147.

Bourke GJ, Dally LE and McGlivray J (1985):
Interpretation and uses of medical statistics. 3rd edition Blackwell Scientific Publications, Oxford, London, Edinburg, Boston, Palo Ato, Melbourne, P: 50.

Brattstrom L, Lindgren A and Israelsson B (1992):
Hyperhomocysteinemia in stroke: prevalence, cause, and relationship to type of stroke and stroke risk factors.
Eur J Clin Invest, 22: 214.

Caspersen CJ, Bloemberg BPM and Saris WHM (1991):
The prevalence of selected physical activities and their relation with coronary heart disease risk factors in edlerly men.
Am J Epidemiol, 133: 1078.

Celermajer DS, Sorensen K, Ryalls M and Robinson J (1993):
Impaired endothelial dysfunction occurs in the systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents.
J Am Coll Cardiol, 22: 854.

Chadefaux B, Coude M, Hamet M, Aupetit J and Kamoun P (1989):
Rapid determination of total homocysteine in plasma.
Clin Chem, 35: 2002.

Chauveau P, Bernadette C and Coude M (1993):
Hyperhomocystienemia, a risk factor for atherosclerosis in chronic uremic patients.
Kidney Int, 43: 572.

Christensen B, Landaas S, Stensvold I and Djurovic S (1999):
Whole blood folate, homocysteine in serum, and risk of first acute myocardial infarction.
Atherosel, 147: 317.

Chu RC and Hull CA (1988):
Total serum homocysteine as an indicator of vitamin B12 and folate status.
Am J Clin Path, 90: 446.

Colbourn AW (1986):
The decline in coronary heart disease mortality.
Del Med J, 58: 351.

Crawford MD, Clayton DG, Stanley F and Shaper AG (1977):
An epidemiological study of sudden death in hard and soft water area.
J Chronic Dis, 30: 69.

D'Angelo A and Selhub J (1997):
Homocysteine and thrombotic disease.
Blood, 90: 1.

Di Minno G, Davi G and Margalione M (1993):
Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.
J Clin Invest, 42: 1400.

Dingeon B (1975):
Ann Biol Clin, 33: 3.

Dryer RL (1970):
In: Fundamentals of clinical chemistry. NW Teitz, ed. WB Saunders. Philadelphia, 329.

Dudman NPB, Hicks C, Lynch JF, Wilcken DEL and Wang J (1991):
Homocysteine thiolactone disoposal by human arterial endothelial cells and serum in vitro.
Arterioscler. Thromb., 11: 663.

Duell PB and Malinow MR (1997a):
Plasma homocysteine a frequent risk factor for atherosclerotic vascular disease.
Cur Opin Lipidol, 8: 28.

Duell PB and Malinow MR (1997b):
Hyperhomocysteinemia is associated with impaired flow-mediated arterial vasodilation.
J Invest Med, 45: 220A.

Duell PB and Malinow MR (1998):
Homocysteinemia and risk of atherosclerosis: a clinical approach to evaluation and management.
Endocrin, 8: 170.

Dzau VJ (1990):
Atherosclerosis and hypertension: Mechanisms and interrelation ships.
J Cardiovasc Pharmacol, 15: 59.

Eaton DL, Fless GM and Kohn WJ (1987):
Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen.
Proc Natl Acad Sci USA, 84: 3224.

El-Allaf M, Chapelle J and El-Allaf (1986):
Differentiating muscle damage from myocardial injury by means of the serum creatine kinase (CK) isoenzyme MB mass measure/total CK activity ratio.
Clin Chem, 32: 291.

Erlich Y, Doolman R, Sela BA (1997):
Hyperhomocysteinemia in the fructose-induced hypertensive-hyperinsulinemic rat. Eighteenth European meeting on Hypertension, June, Milan, Italy.

Finkelstein JD (1990):
Methionine metabolism in mammals.
J Nutr Biochem, 1: 228.

Finkelstein JD and Martin JJ (1986):
Methionine metabolism in mammals: adaptaion to methionine excess.
J Biol Chem, 261: 1582.

Fiskerstrand T, Refsum H, Kvalhein G and Ueland PM (1993):
Homocysteine and other thiols plasma and urine: automated determination and sample stability.
Clin Chem, 39: 263.

Frantzen F, Faaren AL, Alfheim I and Nordhei AK (1998):
An enzyme conversion immunoassay determining total homocysteine in plasma or serum.
Clin Chem, 44: 311.

Frosst P, Blom HJ and Milos R (1995):
A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase.
Nat Genet, 10: 111.

Giannini MJ, Coleman M and Innerfield I (1975):
Antithrombin activity in homocystinuria.
Lancet, 1: 1094.

Giles WH, Kittner SJ, Anda RF and Croft JB (1995):
Serum folate and risk of ischemic stroke. First National Health and Nutrition Examination survey epidemiologic follow-up study.
Stroke, 26: 1166.

Giles WH, Kittner SJ, Croft JB and Anda RF (1998):
Serum folate and risk of coronary heart disease: results from cohort of US adults.
Ann Epidemiol, 8: 490.

Glueck CJ, Shaw P, Lang J and Tracy T (1995):
Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients.
Am J Cardiol, 75: 132.

Graeber JE, Slott JH, Ulane RE, Schulman JD and Stuart M (1982):
Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism.
Pediat Res, 16: 490.

Grove TH (1979):
Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium.
Clin Chem, 25: 560.

Guttormsen AB, Svarstad E, Ueland PM and Refsum H (1995):
Elimination of homocysteine from plasma in subjects with endstage renal failure.
Irish J Med Sci, 164 (Suppl. 15): 18.

Guttormsen AB, Ueland PM and Nesthus L (1996):
Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia: the Hordaland homocysteine study.
J Clin Invest, 98: 2174.

Hajjar KA (1993):
Homocysteine induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.
J Clin Invest, 91: 2873.

Handa K, Kono S and Saku K (1989):
Plasma fibrinogen levels as an independent indicator of the severity of coronary atherosclerosis.
Atherosclerosis, 77: 209.

Harker LA, Harlan JM and Ross R (1983):
Effect of sulfinpyrazone on homocysteine induced-endothelial injury and arteriosclerosis in baboons.
Circ Res, 53: 731.

Harker LA, Ross R and Scott CR (1976):
Homocysteine-induced arteriselerosis: the role of endothelial cell injury and platelet response in its genesis.
J Clin Invest, 58: 731.

Harker LA, Slichter SJ, Scott CR and Ross R (1974):
Homocystinemia. Vascular injury and arterial thrombosis.
N Engl J Med, 291: 537.

Hayashi T, Honda G and Suzuki K (1992):
An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells.
Blood, 79: 2930.

Herbert V (1990):
Development of human folate deficiency. In: Picciano MF, Stokstad ELR, Gregory III JF, editors. Folic acid metabolism in health and disease. Wiley-Liss, Inc., 195.

Hespel P, Lijnen P and Van Hoof R (1988):
Effects of physical endurance training on the plasma renin-angiotensin-aldosterone system in normal man.
J Endocrinol, 116: 443.

Higgins M, Kannel W and Garrison R (1988):
Hazards of obesity-The Framingham experience.
Acta Med Scand, 723: 23.

Hill-Zobel RL, Pycritz RE and Scheffel U (1982):
Kinetics and distribution of indium-labeled platelets in patients with homocysteinuria.
N Engl J Med, 307: 781.

Hoffbrand AV, Newcombe BFA and Mollin DL (1966):
Method of assay of red cell folate activity and the value of the assay as a test for folate deficiency.
J Clin Path, 19: 17.

Israelsson B, Brattstrm LE and Hultberg BL (1988):
Homocysteinemia and myocardial infarction.
Atherosclerosis, 71: 227.

Israelsson B, Brattstrom LE and Refsum H (1992):
Homocysteine in frozen plasma samples: a short cut to establih hyperhomocysteinaemia as a risk factor for arteriosclerosis.
Scand J Clin Lab Invest, 53: 465.

Jacobs RL, House JD, Brosnan ME and Brosnan JT (1998):
Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat.
Diabetes, 47: 1967.

Jacobsen DW (1996):
Determinants of hyperhomocysteinemia: a matter of nature and nurture.
Am J Clin Nutr, 64: 641.

Jacobsen DW, Gatautis VJ and Green R (1989):
Determination of plasma homocysteine by high performance liquid chromatography with flourescence detection.
Anal Biochem, 178: 208.

Jacobsen DW, Gatautis VJ and Green R (1994):
Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex difference and correlation with cobalamine and folate concentration in healthy subjects.
Clin Chem, 40: 873.

Jaques PF, Bostom AG, Williams RR and Ellison RC (1996):
Relation between folate status a common mutation in methylene tetrahydrofolate reductase, and plasma homocysteine concentrations.
Circulation, 93:7.

Jenkins CD (1983):
Psychosocial and behavioral factors. In: Kaplan NM and Stamler J (eds.): Prevention of coronary heart disease: Practical management of the risk factors. Philadelphia, W.B. Saundrs, Company, P. 99.

Jocelyn PC (1987):
Chemical reduction of disulfides.
Methods Enzymol., 143: 246.

Kang SS, Passen EL, Ruggie N, Wong PWK and Sora H (1993):
Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease.
Circulation, 88: 1463.

Kang SS, Wong PWK, Cook HY, Norusis M and Messer JV (1986):
Protein-bound homocysteine. A possible risk factor for coronary artery disease.
J Clin Invest, 77: 1482.

Kannel WB (1987):
Metabolic risk factors for coronary heart disease in women.
Am Heart J, 114: 413.

Kannel WB, D'Agostino RB and Wilson PW (1990):
Diabetes, fibrinogen and risk of cardiovascular disease. The framingham experience.
Am Heart J, 120: 672.

Klevay LM (1984):
The role of copper, zinc and other chemical elements in ischemic heart disease. In: Rennert OM and Chan WY (eds.) Metabolism of Trace Metals in Man. Vol. 1 Boca. Raton, FL, CRC Press, P. 129.

Knuiman JT, West CE and Burema J (1982):
Serum total and high density lipoprotein cholesterol concentrations and body mass index in adult men from 13 countries.
Am J Epidemiol, 116: 631.

Koren MJ, Devereux RB and Casale PN (1991):
Relation of left vntricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.
Ann Intern Med, 114:345.

Landgren F, Israelsson B and Lindgren (1995):
Plasma homocysteine in acute myocardial infarction: hemocysteine-lowering effect of folic acid.
Intern Med, 237: 381.

Langford HG, Stamler J, Wassertheil-Smoller S and Prineas RJ (1986):
All-cause mortality in the hypertension detection and follow up program. Findings for the whole cohort and for persons with less severe hypertension with and without other traits related to risk of mortality.
Prog Cardiovasc Dis, 29: 29.

Larsen K (1972):
Creatinine assay by a reaction-kinetic approach.
Clin Chem Acta, 41: 209.

Larue C, Calzolari C and Bertinchant JP (1993):
Cardiac specific immunoenzymatic assay of troponin I in the early phase of acute myocardial infarction.
Clin Chem, 39: 972.

Lee ME and Wang H (1999):
Homocysteine and hypomethylation: A novel link to vascular disease.
Trends Cardiovasc Med, 9: 49.

Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY and Faraci FM (1996):
Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia.
J Clin Invest, 98: 24.

Lindgren A, Brattstrom L, Norrving B, Hultberg B and Andersson A (1995):
Plasma homocysteine in the acute and convalscent phases after stroke.
Stroke, 26: 795.

Ludmer PL, Selwyn AP, Shook TL and Wayne RR (1986):
Paradoxical vasoconstriction induced by acetyl choline in atherosclerotic coronary arteries.
N Eng J Med, 315: 1046.

Leoni V, Fabiani L and Ticchiarelli L (1985):
Water hardness and cardiovascular mortality rate in Abruzzo, Italy.
Arch Environ Health, 40: 274.

MacMahon SM, Cutler JJ, Furburg CD and Payne GH (1986):
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease.
Prog Cardiovasc Dis, 29: 99.

Mair J, Morandell D and Genser N (1995):
Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponin I and T for acute myocardial infarction.
Clin Chem, 41: 1266.

Malinow MR (1996):
Plasma homocystesine: a risk factor for arterial occlusive disease.
J Nutt, 126: 1238S.

Malinow MR, Axlhelm MK, Meredith MJ, MacDonald VA and Ipson BM (1994):
Synthesis and transsulfuration of homcoysteine in blood.
J Lab Clin Med, 123: 421.

Malinow MR, Duell PB and Hess DL (1998):
Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.
N Engl J Med, 338: 1009.

Malinow MR, Kang SS and Taylor LM (1989):
Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease.
Circulation, 74: 1180.

Malinow MR, Levnson J and Giral P (1995):
Role of blood pressure, uric acid, and hemorheological parameters on plasma homocysteine concentration.
Atherosclerosis, 114: 175.

Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D and Upson B (1990):
Homocysteinemia in daily practice.
Coron Art Dis, 1: 215.

Marshall T, Williams J and Williams KM (1991):
Electrophoresis of serum enzymes and proteins following acute myocardial infarction.
J Chromatogr, 564: 323.

Mayer EL, Robinson K and Jacobsen DW (1995):
Low plasma homocysteine levels predict reduce atheroma burden in patients undergoing coronary intervention: evidence from intravascular ultrasound.
J Am Coll Cardiol, 25: 81A.

Mayer EL, Robinson K and Jacobsen DW (1996):
Homocysteine and coronary atherosclerosis.
J Am Coll Cardiol, 27: 517.

McCully KS (1969):
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
Am J Pathol, 56: 111.

McDonald L, Bray C, Field C and Love F (1964):
Homocysteinemia, thrombosis and blood platelets.
Lancet, 1: 745.

Meade TW, Imeson J and Stirting Y (1987):
Effects of changes in smoking and other characteristics of clotting factors and the risk of ischemic heart disease.
Lancet, 2: 486.

Molgaard J, Malinow MR, Lassvik C and Holm AC (1992):
Hyperhomocysteinemia: an independent risk factor for intermittent claudication.
J Intern Med, 231: 273.

Motulsky AG (1996):
Nutritional ecogenetics homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid.
Am J Hum Genet, 58: 17.

Mudd SH, Levy HL and Skovby F (1995):
Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS and Valle D, editors. The metabolic and molecular basis of inherited disease. 7th edition, New York: McGraw-Hill, Inc., 1279.

Mudd SH, Skovby F, Levy HL (1985):
The natural history of homocystinuria due to cystathionine B-synthase deficiency.
Am J Hum Genet, 37: 1.

Muller-Bardroff M, Freilag H and Scheffold T (1995):
Development and characterization of a rapid assay for bedisde determination of cardiac troponin T.
Circulation, 92: 2869.

Murphy-Chutorion DR and Alderman EL (1994):
The case that hyperhomocysteinemia is a risk factor for coronary artery disease.
Am J Cardiol, 73: 705.

Murray LJ, Bamford KB, Reilly DPJ, McCrum EE and Evans AE (1995):
Helicobacter pylori infection: relation with cardiovascular risk factors, ischemic heart disease and social class.
Br Heart J, 74: 497.

Nash BJ and Lim-Yin YW (1979):
A discrepancy between plasma and serum values for vitamin B12 and folate.
Med Lab Sci, 39: 297.

Nehler MR, Taylor LM and Porter JM (1997):
Homocysteine as a risk factor for atherosclerosis.
Cardiovascular Pathology, 6:1.

Nishinaga M, Ozawa T and Shimada K (1993):
Homocysteien a thrombogenic agent, suppresses anticoagulant heparin sulfate expression in cultured protein aortic endothelial cells.
J Clin Invest, 92: 1381.

Nordstrom M and Kjellstrom T (1992):
Age dependency of cystathionine betasynthase activity in human fibroblasts in homocysteinemia and atherosclerotic vascular disease.
Atherosclerosis, 94: 213.

Nygard O, Nordrehaug JE, Refsum H and Ueland PM (1997):
Plasma homocysteine levels and mortality in patients with coronary artery disease.
N Engl J Med, 337: 230.

Oster O, Dahm M, Oelert H and Prellwitz W (1989):
Concentrations of some trace elements (Se, Zn, Cu, Fe, Mg, K) in blood and heart tissue of patients with coronary heart disease.
Clin Chem, 35: 851.

Owens GK (1995):
Regulation of differentiation of vascular smooth muscle cells.
Physiol Rev, 75: 487.

Palareti G and Coccheri S (1989):
Lowered antithrombin III activity and other clotting changes in homocystinuria: effect of pyridoxine-folate regimen.
Haemostasis, 19: 24.

Patel P, Mendall MA and Caningtom D (1995):
Association of Helicobacter pylori and chlamydia and pneumonia infections with coronary heart disease and cardiovascular risk factor.
Br Med J, 311: 711.

Perry IJ, Refsum H, Morris RW, Ebrahim SB and Ueland PM (1995):
Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.
Lancet, 346: 1395.

Puleo PR, Meyer D and Wathen C (1994):
Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction.
N Engl J Med, 331: 561.

Robitzsch G, Mair J and Lechleitner P (1995):
Immunoenzymometric assay of human glycogen phosphorylate isoenzyme BB in diagnosis of ishcemic myocardial injury.
Clin Chem, 41: 966.

Rautela GS and Liedtk RJ (1978):
Automatic enzymic measurement of total cholesterol in serum.
Clin Chem, 24: 108.

Refsum H, Helland S and Ueland PM (1985):
Radioenzymic determiantion of homocysteine in plasma and urine.
Clin Chem, 31: 624.

Refsum H, Ueland PM and Srardal AM (1989):
Fully automated fluorescence assay for determining total homcysteine in plasma.
Clin Chem, 35: 1921.

Regan TJ (1990):
Alcohol and cardiovascular system.
JAMA, 264: 377.

Reimer KA and Jenning RB (1991):
Myocardial ischemia, hypoxia and infarction: In Fozzard HA, Hober E and Jennings RB (eds.): The Heart and Cardiovascular system. 2nd ed. New York, P. 1875.

Richie JPJ and Lang CA (1987):
The determination of glutathione, cysteine and other thiols and disulfides in biological samples using high performance liquid chromatography with duel electrochemical detection.
Anal Biochem, 163: 9.

Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR and Stampfer MJ (1997):
Interrelation of hyperihomocyteinemia, factor V Leiden, and risk of future venous thromboembolism.
Circulation, 95: 1777.

Rimm EB, Willett WC and Hu FB (1998):
Folate and vitamin 136 from diet and supplements in relation to risk coronary heart disease among women.
J Am Med Assoc, 279: 359.

Roberts R (1990):
Enzymatic estimation of infarct size: thrombolysis induced its demise: Will it now rekindle its renaaissance?
Circulation, 81: 707.

Robinson K, Arheart K and Refsum H (1998):
Low circulating folate and vitamine B6 concentrations. Risk factor for stroke, peripheral vascular disease and coronary artery disease.
Circulation, 97: 437.

Rodgers GM and Kane WH (1986):
Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.
J Clin Invest, 77: 1909.

Rogers GM and Conn MT (1990):
Homocysteien, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.
Blood, 75: 895.

Rolland PH, Friggi A and Barlatier A (1995):
Hyperhomocysteinemia induced vascular damage in minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations.
Circulation, 91: 1161.

Ross R (1993):
The pathogenesis of atherosclerosis: a prespective for the 1990s.
Nature, 362: 801.

The Scandinavian Simvastatin Survival Study: The 4S investigators (1994):
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
Lancet, 344: 1383.

Schmitz C, Lindpaintner K and Verheof P (1996):
Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case control study.
Circ, 94: 1812.

Selhub J, Jacques PF, Wilson PWF, Rush D and Rosenbeg IH (1993):
Vitamin status and intake as primary determinates of homocysteinemia in an elderly population.
JAMA., 270: 2693.

Sellier P, Corona P and Udoin P (1988):
Influence of training on blood lipids and coagulation.
Eur Heart J, 9: 32.

Sharabi Y, Doolmon R, Rosenthal T and Grossman E (1999):
Homocysteive level in hypertensive patients with a history of cardiac or cerebral atherthrombotic events.
AJH, 12, 766.

Sherif K, Suummer AF and Major A (1998):
Plasma homocysteine and cardioviascular risk factors in African- American Women.
Am J Hypertens, 11: 25 A.

Siri PW, Verhoef P and Kok FJ (1998):
Vitamin B6, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis.
J Am Cou Nutr, 17 : 435.

Smoline LA, and Sneider JA (1988):
Measurement of total plasma cysteamine using high performance liquid chormotography with electrochemical detection .
Anal. Biochem, 168 : 374.

Stabler SP, Lindenboum J, Savage DG and Allen RH (1993):
Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency.
Blood, 81:340.

Stabler SP, Marcell PD, Podell ER and Allen RH (1987):
Quantitation of total homocysteine, total cysteine, and methinonine in normal serum and urine using cappillary gas chromatography-mass spectrometry.
Anal Biochem, 162 : 185.

Stamler TS, Obsorne JA, Jaraki O, Rabbani LE, Mullins M, Single D and Loscalzo J (1993):
Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen.
J Clin Invest, 91 : 308.

Starkebaum G and Harlan JM (1986):
Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocystein.
J Clin Invest, 77: 1370.

Stolar MW (1988):
Atherosclerosis in diabetes. The role of hyperinsulinemia.
Metabolism, 37 : J 1.

Sung JJY and Sanderso JE (1996):
Hyperhomocystainemia, Helicobacter pylori and coronary artery diseases.
Heart, 76: 305.

Tawakol A, Omland T and Gerhard M (1997):
Hyperhomocystainemia is associated with impaired endothelium dependent vasodilatation in humans.
Circulation, 95 : 1119.

Tiwari AK, Gode JD and Dubey GP (1989):
Effect of cigarette smoking on serum total cholesterol and HDL in normal subjects and coronary heart disease patients.
Indian Heart. J, 41: 92.

Tsai JC, Perrella MA, and Yoshizumi M (1994):
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atheroschleosis.
Proc Natl Acad Sci USA, 41 : 6369.

Tsai JC, Wang H and Perrella MA (1996):
Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells.
J Clin invest, 79 : 146.

Ubbink JB, Vermaak WJH, Bennett JM and Becker PJ (1991a):
The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heat disease.
Klin Wochenschr, 69 : 527.

Ubbink JB, Vermaak WJH and Bissbort SB (1991b):
Rapid high-performance liquid chromatographic assay for total homocysteine levels in serum.
J Chromatorg, 565 : 441.

Ubbink JB, Vermaak WJH, Vander Merw A and Becker PJ (1994):
Vitamin requirements for the treatment of hyperhomocysteinemia in humans.
J Nutr, 124 : 1927.

Ueland PM and Refsum H (1989):
Plasma homocystiene, a risk factor for vascular disease: plasma levels in health, disease and drug therapy.
J Lab Clin Med, 114: 473.

Ueland PM, Refusm H and Brattstrom L (1992):
Plasma homocysteine and cardivoascular disease. In: Francis R.B. Jr. Editor. Atherosclerotic cardiovascular disease, homeostasis, and endothelial function. New York: Marcel Dekker, 183 – 236.

Ueland PM, Refsum H Slabler SP and Malinow MR (1993):
Total homocysteine in plasma or serum: methods and clinical applications.
Clin Chem, 93 : 1764.

Valentive RJ, Kaplam HS and Green R (1996):
Lipoprtein (a), homocyteine and hypercoagulable state in young men with premature peripheral atherosclerosis : a prospective, controlled analysis.
J Vasc Surg, 23 : 53.

Van Bockxmeer FM, Mamotte CDS Vasikaran SD and Taylor RR (1997):
Methylene tetrahydrofolate reducates gene and coronary artery disease.
Circulation, 95 : 21.

Van der Mooren MJ, Wooters MGAJ, Blom HJ, Scellekens LA, Eskes TKAB and Rolland R (1994):
Hormone replacement therapy may reduce high serum homocystiene in post menopausal women.
Eru J Clin Invest, 14 : 733.

Verhoef P, Kok FJ and Kruyssen DA (1997):
Plasma total homocysteine, B vitamins, and risk of coronary athersclerosis.
Arterioscler Thromb Vasc Biol, 17 :989.

Vester B and Rasmussenk (1991):
High performance liquid chromatogyphy method for rapid accrurate determination of homocysteine in plasma and serum.
Eur J Clin Chem Clin Biochem, 29:549.

Van Eckardstein A, Malinow MR and Upson B (1994):
Effects of age, lipoproteins and homeostatic parameters on the role of homocysteinemia as a cardiovascular risk factor in men.
Arterioscler Thrombs, 4 : 960.

Wall RT, Harlan JM Harker LA and Striker GE (1980):
Homocysteine induced endothelial cell injury in vitro: a model for the study of vascular injury.
Thromb Res, 18 : 113.

Wang XL, Dural N, Gai H and Adachi T (1999):
Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population.
Atheroscl, 146: 133.

Weinstein DB and Heiden TG (1988):
Antiatherogenic effects of calcium channel blocker.
Am J Med, 84: 102.